Fosun Pharma: Holding subsidiary HLX18 receives approval for clinical trials.

Fosun Pharma announced on March 20th that its subsidiary Fosun Hanlin, a controlled subsidiary of the company, has received notification from the National Medical Products Administration approving its self-developed drug HLX18 for conducting Phase I clinical trials for the treatment of various solid tumors. The drug is a biosimilar to nivolumab, intended for indications such as melanoma and non-small cell lung cancer. As of February 2026, the cumulative research and development investment in HLX18 by the group is approximately 59 million yuan. Previously, the drug had been approved by the US FDA for Phase I clinical trials starting in December 2025. The company notes that HLX18 still needs to complete clinical research in China and obtain approval before it can be marketed, and there is a risk of research and development failure.